In considering the crosstalk between genetic changes in prostate cancer and metabolic dysregulation, it is helpful to focus on some of the principal oncogenic drivers—AR activity, c-Myc amplification and overexpression and mutations in phosphatase and tensin homolog deleted on chromosome 10 (PTEN) and in TP53. Here, MYC is linked to prostate cancer.